The infusion of seed capital enables Courage Therapeutics to accelerate R&D on high‑need obesity and wasting disease treatments, a market projected to grow sharply as prevalence rises. Investor backing signals confidence in the company’s approach and may attract further funding for later‑stage trials.
Comments
Want to join the conversation?
Loading comments...